Immune escape: A critical hallmark in solid tumors DOI
Keywan Mortezaee

Life Sciences, Journal Year: 2020, Volume and Issue: 258, P. 118110 - 118110

Published: July 19, 2020

Language: Английский

A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells DOI Creative Commons
Sijin Cheng, Ziyi Li, Ranran Gao

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(3), P. 792 - 809.e23

Published: Feb. 1, 2021

Tumor-infiltrating myeloid cells (TIMs) are key regulators in tumor progression, but the similarity and distinction of their fundamental properties across different tumors remain elusive. Here, by performing a pan-cancer analysis single from 210 patients 15 human cancer types, we identified distinct features TIMs types. Mast nasopharyngeal were found to be associated with better prognosis exhibited an anti-tumor phenotype high ratio TNF+/VEGFA+ cells. Systematic comparison between cDC1- cDC2-derived LAMP3+ cDCs revealed differences transcription factors external stimulus. Additionally, pro-angiogenic tumor-associated macrophages (TAMs) characterized diverse markers composition appeared certain somatic mutations gene expressions. Our results provide systematic view highly heterogeneous suggest future avenues for rational, targeted immunotherapies.

Language: Английский

Citations

998

Neutrophil diversity and plasticity in tumour progression and therapy DOI
Sébastien Jaillon, Andrea Ponzetta, Diletta Di Mitri

et al.

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 20(9), P. 485 - 503

Published: July 21, 2020

Language: Английский

Citations

897

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects DOI Creative Commons

Weiwei Tang,

Ziyi Chen, Wenling Zhang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2020, Volume and Issue: 5(1)

Published: June 10, 2020

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib currently an effective first-line therapy. Unfortunately, the development drug resistance to becoming increasingly common. This study aims identify factors contributing ways mitigate resistance. Recent studies have shown that epigenetics, transport processes, regulated death, microenvironment are involved in HCC subsequent progression. summarizes discoveries achieved recently terms principles outlines approaches suitable for improving therapeutic outcomes patients.

Language: Английский

Citations

780

COVID-19: A promising cure for the global panic DOI Open Access
Balachandar Vellingiri, Kaavya Jayaramayya, Mahalaxmi Iyer

et al.

The Science of The Total Environment, Journal Year: 2020, Volume and Issue: 725, P. 138277 - 138277

Published: April 4, 2020

Language: Английский

Citations

639

Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells DOI Creative Commons
Jia Xiong, Jia He,

Jun Zhu

et al.

Molecular Cell, Journal Year: 2022, Volume and Issue: 82(9), P. 1660 - 1677.e10

Published: March 22, 2022

Language: Английский

Citations

426

Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment DOI Creative Commons
Khiem C. Lam, Romina E. Araya, April Huang

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(21), P. 5338 - 5356.e21

Published: Oct. 1, 2021

Language: Английский

Citations

393

Radiotherapy combined with immunotherapy: the dawn of cancer treatment DOI Creative Commons

Zengfu Zhang,

Xu Liu,

Dawei Chen

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: July 29, 2022

Abstract Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic effect on remote and non-irradiated tumor deposits, which called abscopal effect. The view RT as a simple treatment has dramatically changed in recent years, it now widely accepted that provoke immune response gives strong rationale the combination immunotherapy (iRT). Nevertheless, several points remain to be addressed such interaction system, identification best schedules with (IO), expansion mechanism amplify iRT. To answer these crucial questions, we roundly summarize underlying showing whole landscape clinical trials attempt identify In consideration rarity effect, propose occurrence induced by radiation promoted 100% molecular genetic level. Furthermore, “radscopal effect” refers using low-dose reprogram microenvironment may overcome resistance Taken together, could regarded trigger antitumor response, help IO used radical added into current standard regimen patients metastatic cancer.

Language: Английский

Citations

379

Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets DOI Creative Commons
Yan Tie, Fan Tang, Yuquan Wei

et al.

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: May 18, 2022

Abstract Immunotherapies like the adoptive transfer of gene-engineered T cells and immune checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some patients refractory or resistant to these therapies, mechanisms underlying tumor resistance have not been fully elucidated. Immunosuppressive such as myeloid-derived suppressive cells, tumor-associated macrophages, neutrophils, regulatory (Tregs), dendritic critical factors correlated with resistance. In addition, cytokines secreted by immunosuppressive also mediate progression escape Thus, targeting related signals is promising therapy improve efficacy immunotherapies reverse even certain success in preclinical studies specific types cancer, large perspectives unknown therapies undesirable outcomes clinical patients. this review, we comprehensively summarized phenotype, function, potential targets microenvironment.

Language: Английский

Citations

321

IDO Expression in Cancer: Different Compartment, Different Functionality? DOI Creative Commons
Annabel Meireson, Michaël Devos, Liève Brochez

et al.

Frontiers in Immunology, Journal Year: 2020, Volume and Issue: 11

Published: Sept. 24, 2020

Indoleamine 2,3-dioxygenase 1 (IDO1) is a cytosolic haem-containing enzyme involved in the degradation of tryptophan to kynurenine. Although initially thought be solely implicated modulation innate immune responses infectious conditions, subsequent discoveries demonstrated IDO1 as mechanism acquired tolerance. In cancer expression / activity has been observed tumor cells well tumor-surrounding stroma which composed endothelial cells, fibroblasts and mesenchymal cells. IDO also reported peripheral blood. This manuscript reviews available data on expression, mechanisms its induction function for each these compartments. In-depth study biological according expressing (tumor) cell can help understand if when IDO1-inhibition play role therapy.

Language: Английский

Citations

159

Tumor-associated myeloid cells: diversity and therapeutic targeting DOI Open Access
Alberto Mantovani, Federica Marchesi, Sébastien Jaillon

et al.

Cellular and Molecular Immunology, Journal Year: 2021, Volume and Issue: 18(3), P. 566 - 578

Published: Jan. 20, 2021

Language: Английский

Citations

158